Institute News

Scientists discover role for gene in immune system

Researchers at the UCL Institute of Immunity and Transplantation (IIT) have discovered that a single gene plays an important role in ensuring humans are able to fight infections. More...

Open Day presentations now online

Presentations from the Institute of Immunity and Transplantation Open Day 27 June 2014 can now be viewed online.

The latest trials and other clinical studies approved to take place via the Institute of Immunity and Transplantation:

Clinical trials and other patient-related studies

Eradication of HIV reservoirs

RIVER: Research in viral eradication of HIV reservoirs.

Canagliflozin for diabetes and diabetic nephropathy

CREDENCE: A randomized, double-blind, event-driven, placebo-controlled, multicenter study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with type 2 diabetes mellitus and diabetic nephropathy.

Natural history and biomarkers in Alport syndrome

A natural history study to observe disease progression, standard of care and investigate biomarkers in Alport syndrome patients.

Efficacy and safety of tolvaptan in autosomal dominant polycystic kidney disease

Phase 3b, multi-center, randomized-withdrawal, placebo-controlled, double-blind, parallel-group trial to compare the efficacy and safety of tolvaptan (45 to 120 mg/day, A Phase split-dose) in subjects with chronic kidney disease between late stage 2 to early stage 4 due to autosomal dominant polycystic kidney disease.

Inhaled treatment for COPD

A randomized, double blind, placebo-controlled 2-way crossover study to evaluate the
efficacy, safety and tolerability of PF-03715455 administered twice daily by inhalation for 4 weeks in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).

Switching to new single-tablet regimen in HIV

A Phase 3, randomized, active controlled, open label study to evaluate switching to a
darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily single
tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically suppressed human immunodeficiency virus type 1 (HIV1) infected subjects.

Dupilumab in atopic dermatitis

A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moderate to severe atopic dermatitis (AD).

Safety of tolvaptan in autosomal dominant polycystic kidney disease

A phase 3b, multi-centre, open-label trial to evaluate the long term safety of titrated
immediate-release tolvaptan (OPC 41061, 30 mg to 120 mg/day, split dose) in subjects with autosomal dominant polycystic kidney disease.

Treatment of psoriatic arthritis

A subject-blind, investigator-blind, randomized placebo-controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of multiple doses of ucb4940 in subjects with psoriatic arthritis (pa007 study).

Masitinib for rheumatoid arthritis responding poorly to other treatments

A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, parallel groups, Phase 2b/3 study to compare efficacy and safety of masitinib to methotrexate, in treatment of patients with active rheumatoid arthritis with inadequate  response to 1. methotrexate or to 2. any DMARD including at least one biologic drug if patients previously failed methotrexate or to 3. methotrexate in combination with any DMARD including biologic drugs. 

Brincidofovir for ebola virus disease

An open label, multi-center study of the safety, tolerability and antiviral activity of
brincidofovir (CMX001) for treatment of Ebola virus disease.

Treatment of rheumatoid arthritis

A phase 3b/4 randomised double-blind study of 5 mg of tofacitinib with and without methotrexate in comparison to adalimumab with methotrexate in subjects with moderatly to severely active rheumatoid arthritis. More...

Combination therapy for lupus nephritis

RITUXILUP: An open label randomised multicentre controlled trial of RITUXImab and mycophenolate mofetil (MMF) without oral steroids for the treatment of LUPus nephritis.

Detection of TB infection

Evaluation of a CD4/CD8 interferon gamma release assay for the detection of tuberculosis infection.

HIV management

Study number: GS-US-236-014.

Riociguat for diffuse cutaneous systemic sclerosis

A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat in patients with diffuse cutaneous systemic sclerosis (dcSSc).

Riociguat for pulmonary arterial hypertension not responding adequately to PDE-5i

RESPITE: An open-label, international, multicenter, single-arm, uncontrolled, phase IIIb study of riociguat in patients with pulmonary arterial hypertension (PAH) who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors (PDE-5i).

Fostamatinib in IgA nephropathy

A phase 2, multi-centre, randomised, double-blind, ascending-dose, placebo-controlled clinical study to assess the safety and efficacy of fostamatinib in the treatment of IgA nephropathy.

Re-formulation of raltegravir in HIV

Reformulated raltegravir q.d. (1200) versus raltegravir b.i.d (400mg) in ART-naïve HIV patients.

Chronic kidney disease pilot study

HARP-III: randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease.

Treatment of lupus nephritis

A phase 1b, randomized, double blind, placebo controlled, safety, tolerability and
pharmacokinetic study of multiple rising doses of MLN9708 for the treatment of subjects With ISN/RPS class III or IV lupus nephritis.

Treatment of Raynaud's phenomenon in systemic sclerosis

A multi-centre, double-blind, randomized, placebo-controlled, parallel group, exploratory phase 2 study to assess efficacy and safety of selexipag in adult subjects with Raynaud’s phenomenon secondary to systemic sclerosis.

Non-invasive assessment in liver disease

Bio-banking and fibrosis evaluation through non-invasive assessment in autoimmune liver diseases. 

Monoclonal antibody treatment for chronic plaque psoriasis

Signature: Secukinumab in patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFα antagonists: A clinical trial evaluating treatment results. 

Genetics of lupus

Sequencing-based genetic analysis of systemic lupus erythematosus.

Page last modified on 06 feb 14 12:27